Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Giuseppe MC Rosano"'
Publikováno v:
ESC Heart Failure, Vol 10, Iss 2, Pp 1294-1304 (2023)
Abstract Aims Iron deficiency is a common finding among patients with heart failure (HF) and is associated with adverse outcomes, including decreased quality of life, increased risk of hospitalization, and decreased survival. Intravenous ferric carbo
Externí odkaz:
https://doaj.org/article/9c503788dd1847b79fbd01eb5d2d8a2e
Publikováno v:
Cardiac Failure Review, Vol 8, Iss , Pp - (2022)
The aging population, higher burden of predisposing conditions and comorbidities along with improvements in therapy all contribute to the growing prevalence of heart failure (HF). Although the majority of trials have not demonstrated age-dependent he
Externí odkaz:
https://doaj.org/article/0bb983f9d755413ca893e04f4fec187f
Publikováno v:
Cardiac Failure Review, Vol 5, Iss 3, Pp 130-132 (2019)
Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF). To reduce mortality in these patients, RAASi should be uptitrated to the maximally to
Externí odkaz:
https://doaj.org/article/c79eef101b394565888d7685ae8638f1
Autor:
Giuseppe MC Rosano, Petar Seferović
Publikováno v:
International Cardiovascular Forum Journal, Vol 18, Pp 31-35 (2019)
Impaired glucose metabolism and diabetes are both very common in HF, and associated with worse functional status and prognosis. More lenient rather than strict glycaemic control is advised in patients with HF. In patients with diabetes and HF glycaem
Externí odkaz:
https://doaj.org/article/c5e01c1bed804d3581193c2f67d1184a
Autor:
Giuseppe MC Rosano, Andrew JS Coats
Publikováno v:
International Cardiovascular Forum Journal, Vol 17, Pp 22-25 (2019)
Heart failure is associated with altered cardiac metabolism, in part, due to maladaptive mechanisms, in part secondary to comorbidities such as diabetes and ischaemic heart disease. The metabolic derangements taking place in heart failure are not lim
Externí odkaz:
https://doaj.org/article/f147ea79dd4340b3915a6dbedfedc54b
Autor:
Giuseppe MC Rosano, Piotr Ponikowski
Publikováno v:
International Cardiovascular Forum Journal, Vol 18, Pp 7-10 (2019)
Inotropes historically all increased intra-cellular calcium levels and they commonly causedintracellular Ca2+ overload and triggered malignant arrhythmias. The myosin activators, such as Omecamtiv Mecarbil (OM), increase myosin activity and function,
Externí odkaz:
https://doaj.org/article/13bcf8463a6d49b88e3e544b2bdb5e62
Autor:
Giuseppe MC Rosano
Publikováno v:
International Cardiovascular Forum Journal, Vol 17, Pp 2-5 (2019)
The treatment of heart failure has included vasodilators, positive inotropes and most successfully neuro-hormonal blockade.Recent research has looked at metabolic and immune modulatory approaches, and implantable, mainly electrical devices. The near
Externí odkaz:
https://doaj.org/article/beb2c6c43b4345399c106df4150df5dc
Autor:
Giuseppe MC Rosano
Publikováno v:
International Cardiovascular Forum Journal, Vol 17, Pp 19-21 (2019)
After the withdrawal of flosequinan in the early 1990s, because of an increased risk of mortality and fatal arrhythmias, the bar for the approval of new drugs in heart failure has beenraised and regulatory agencies have requested evidence for the eff
Externí odkaz:
https://doaj.org/article/22cbe965030f4b919f0cb014fdc112ef
Autor:
Giuseppe MC Rosano, Cristiana Vitale
Publikováno v:
International Cardiovascular Forum Journal, Vol 17, Pp 26-28 (2019)
The novel first-in-class If channel antagonist, Ivabradine, is effective in improving clinical outcomes and functional capacity, in patients with HF, as well as demonstrating useful anti-anginal and protective anti-ischaemic effects. It can help impr
Externí odkaz:
https://doaj.org/article/6be4d0f4f271424c8a50e2f1d042b26e
Autor:
Ilaria Spoletini, Giuseppe MC Rosano
Publikováno v:
International Cardiovascular Forum Journal, Vol 17, Pp 34-36 (2019)
The role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is wellrecognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs
Externí odkaz:
https://doaj.org/article/848580effa6e45b8b6b1356181b43207